Literature DB >> 11905764

Management of hot flashes in breast-cancer survivors.

C L Loprinzi1, D L Barton, D Rhodes.   

Abstract

Hot flashes can be a major problem for patients with a history of breast cancer. Although oestrogen can alleviate hot flashes to a large extent in most patients, there has been debate about the safety of oestrogen use in survivors of breast cancer. The decrease in hot flashes achieved with progestational agents is similar to that seen with oestrogen therapy but, again, there is some debate about the safety of progestational agents in patients with a history of breast cancer. Several alternative substances have therefore been investigated. These include a belladonna alkaloid preparation, clonidine, soy phyto-oestrogens, vitamin E, gabapentin, and several of the newer antidepressants, with venlafaxine being the best studied to date. Several studies in progress may provide better non-hormonal means of treating hot flashes in the future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11905764     DOI: 10.1016/S1470-2045(00)00289-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  6 in total

Review 1.  Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.

Authors:  Rodney Baber; Martha Hickey; Michelle Kwik
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Intermittent 96-Hour Auricular Electroacupuncture for Hot Flashes in Patients with Prostate Cancer: A Pilot Study.

Authors:  Tyvin Rich; Gerald W Porter; Luisel Ricks-Santi; Tzvi Milshtein; Thomas Corbin
Journal:  Med Acupunct       Date:  2017-10-01

3.  Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors.

Authors:  Karen J Wernli; John M Hampton; Amy Trentham-Dietz; Polly A Newcomb
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-08       Impact factor: 2.890

4.  Pilot evaluation of a stellate ganglion block for the treatment of hot flashes.

Authors:  Deirdre R Pachman; Debra Barton; Paul E Carns; Paul J Novotny; Sherry Wolf; Breanna Linquist; Sadhna Kohli; DeAnne R Smith; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-05-23       Impact factor: 3.603

5.  Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.

Authors:  Deirdre R Pachman; Jason M Jones; Charles L Loprinzi
Journal:  Int J Womens Health       Date:  2010-08-09

6.  20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Authors:  Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes
Journal:  N Engl J Med       Date:  2017-11-09       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.